# Medicare Part D **Medicare Part D** is Medicare's outpatient prescription-drug benefit, created in 2003 and delivered entirely through private plans and their [[Pharmacy Benefit Managers]]. Its founding statute included the **"non-interference" clause** barring the government from negotiating prices — the single biggest reason U.S. [[Drug Pricing]] ran higher than peer nations for two decades. ## Why It Matters Part D is the battleground where drug-pricing policy actually operates. The [[Inflation Reduction Act]] reforms land here: [[Drug Price Negotiation]] (breaking non-interference), a $35 insulin cap, a $2,000 annual out-of-pocket cap, and a redesign shifting more catastrophic-cost liability onto plans and manufacturers. Because Part D is privately administered, the savings depend on how plans and PBMs pass them through — the recurring gap between reform on paper and price at the counter. See [[Drug Pricing]] and [[Medicare Advantage]]. ## The premium-stabilization sequence The out-of-pocket cap is still law. What is being removed is the scaffolding that was built to absorb its side effects. The sequence matters more than any single step: 1. **2022 — the IRA redesign.** Capping out-of-pocket costs and shifting catastrophic liability onto plans raised plan risk, which showed up immediately as volatile and sharply varying **standalone** drug-plan premiums. 2. **2024–2025 — the demonstration.** [[CMS]] created the **Part D Premium Stabilization Demonstration**, a voluntary program for standalone prescription drug plans implemented for CY 2025. It reduced beneficiary premiums by up to $15 in 2025 and capped any single plan's year-over-year premium increase at $35, with smaller reductions in 2026. GAO estimated the cost at roughly **$9.8 billion across 2025 and 2026**. 3. **The demonstration worked on its own terms.** Standalone enrollment rose from **22.8 million in 2024 to 24.9 million in 2026**, and average monthly premiums fell by **$26 in 2025 and $16 in 2026**. 4. **July 28, 2026 — termination announced.** In the same fact sheet releasing preliminary CY 2027 bid information, CMS announced it would **discontinue the demonstration at the end of CY 2026** — a year earlier than expected — because plan sponsors now had "sufficient experience under the redesigned Part D benefit," returning the program "to operating under traditional market conditions in CY 2027." The move was first reported by the [[Wall Street Journal]]. 5. **The 2027 numbers as released.** The national average monthly bid amount was set at **$296.05**, roughly a 24 percent increase. The national base beneficiary premium was set at **$41.33**; the IRA separately caps annual increases in that base premium at 6 percent per year through 2029, which limits but does not eliminate the pass-through. 6. **Not yet known.** Actual 2027 plan premiums are not public. CMS releases the Medicare Advantage and Part D landscape in **mid-to-late September 2026** — meaning the real numbers land inside the midterm campaign. ## The claim and the pushback [[Mehmet Oz]] defended the termination on X the day it was announced: "We are stabilizing the market so this bailout is no longer needed," adding that premiums would rise "by less than $10 for most Medicare recipients, with many even seeing LOWER premiums," and that other price policies — the [[Most-Favored-Nation Drug Pricing Deals]] and $50-a-month GLP-1 access for seniors — would continue. See [[Mehmet Oz - stabilizing the market]]. An administration official told ABC News about half of enrollees would see either an increase under $10 or a decrease. Outside estimates run higher. KFF put the current subsidized average standalone premium near **$36 a month** and estimated ending the demonstration could raise some premiums by as much as **$20**. On **August 4, 2026**, fifty-one House Democrats led by Rep. Chris Pappas of New Hampshire wrote to Oz demanding immediate reversal, stating that roughly **75 percent of current enrollees** are likely to see costs increase, and asking CMS to release whatever analysis supports its claim that insurers no longer need the payments. Governor Kathy Hochul and Senator Kirsten Gillibrand warned of increases up to 40 percent for New York enrollees. As of late August 2026 CMS had not reversed the decision and no litigation had been filed. Note the framing move in the word *bailout*. The payments went to insurers, but their function was premium suppression for enrollees; calling them a bailout converts a cost shift onto beneficiaries into an act of fiscal discipline. Administration officials simultaneously blamed the IRA for the premium instability the demonstration was created to absorb. ## Where it points Standalone Part D plans are the drug-coverage route for people who stay in **traditional** Medicare. [[Medicare Advantage]] plans bundle drug coverage instead. Raising standalone premiums therefore makes traditional Medicare more expensive relative to Part C without any rule change to Part C — and pushing enrollment toward Medicare Advantage is an explicit [[Project 2025]] objective. That is the structural stake underneath a technical demonstration ending. ## See also - [[Insulin and the Politics of Drug Pricing]] — a century-old drug priced as a luxury, and the fight over capping it